Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ad.hIFN-β · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Ad.hIFN-β (BG00001, IDEC-201) | DRUG | - |
Inclusion Criteria: * Subjects with histologically confirmed hepatic metastases from primary colorectal carcinoma. * Not amenable to complete surgical resection for attempted cure as determined by the Principal Investigator (PI). * Tumor progression after prior therapy for colorectal carcinoma, inc...
Ad.hIFN-β is an investigational gene therapy being studied for the treatment of refractory colorectal carcinoma with liver metastases. It is administered to patients with colorectal carcinoma that has spread to the liver. The drug is currently in Phase 1 clinical development and is not approved by regulatory authorities.
Ad.hIFN-β is designed to deliver the gene for interferon-beta, a cytokine with antiviral, antiproliferative, and immunomodulatory activities. By expressing interferon-beta locally in the tumor, the therapy aims to inhibit tumor growth and stimulate an immune response against cancer cells. The specific molecular target is not disclosed in the available information.
Ad.hIFN-β is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The company is conducting clinical research on this investigational gene therapy for colorectal carcinoma with liver metastases.
Ad.hIFN-β is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The Phase 1 trial has been completed, and the drug remains in early-stage clinical research.
Ad.hIFN-β has been studied in one completed Phase 1 clinical trial, registered as NCT00107861. This trial, titled 'Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases,' enrolled 44 participants in the United States. The trial was uncontrolled and not randomized or double-blinded.
Ad.hIFN-β is not the same as interferon-beta itself. It is a gene therapy vector that delivers the gene for human interferon-beta into cells. The drug is designed to produce interferon-beta locally within the tumor, potentially offering a targeted approach compared to systemic interferon-beta administration.